Nontumorous attenuation changes on CT arterial portography

CT during arterial portography: effects of precontrast injection of prostaglandin E1 into the superior mesenteric artery

Prostaglandin E1 (PGE1) is a vasodilator that increases portal venous flow. Hepatic CT during arterial portography (CTAP) was performed in 42 patients with and without PGE1 to compare peak hepatic enhancement and nontumorous abnormalities. Although no significant differences in peak hepatic enhancement were observed (71 +/- 12 HU for CTAP with PGE1; 74 +/- 34 HU for CTAP without PGE1), the number of nontumorous abnormalities for CTAP with PGE1 (n = 11) was significantly lower than that for CTAP without PGE1 (n = 24) (p < 0.01, Wilcoxon signed rank test). CTAP combined with PGE1 therefore represents a useful method to study lesions of the liver, as the number of nontumorous abnormalities observed is significantly reduced and liver parenchyma can be scanned more evenly.

Diffuse perfusion abnormality of the liver parenchyma on angiography-assisted helical CT in relation to cirrhosis and previous treatments: a potential diagnostic pitfall for detecting hepatocellular carcinoma

We evaluated diffuse perfusion abnormality of the liver parenchyma in relation to cirrhosis and previous treatments and estimated its potential limitation in detecting hepatocellular carcinomas (HCCs) on CT arterial portography (CTAP) and CT hepatic arteriography (CTHA). Sixty-one patients of liver cirrhosis with or without HCC received both CTAP and CTHA. Irregular defects of enhancement of the liver parenchyma on CTAP were noted in 37 of 61 patients (60.7%) and compensatory arterial perfusion in these defects on CTHA was noted in 30 of 37 patients (81.1%). Most patients had segmental or mixed patterns of enhancement. In patients with severe cirrhosis, irregular enhancement was often noted. The irregularity was also more often in patients who had had previous treatments. Four of 40 HCC nodules in 18 patients with severe irregular perfusion were not detected on CTAP and CTHA. Diffuse perfusion abnormalities of the liver parenchyma on CTAP and CTHA would decrease the accuracy of tumor detection in HCC patients.